BPC-157 for Injury Recovery: Protocol, Dosing, and What to Expect
Evidence strength: strong
What this protocol is for
BPC-157 is the precision tool the recovery side of the peptide space has settled on as default. Not magic. Mechanism. Angiogenesis (new blood supply into injured tissue), fibroblast migration, growth-factor receptor upregulation. The repair signaling your body already runs, pushed harder.
Research shows the mechanism mapping is real, particularly for soft tissue, gut, and ligament work where the underlying biology is well characterised. Anecdotally, users report the injury stuck at the four-week wall finally starts moving. A recurring tendon issue responds. Chronic non-healing tissue gets unstuck. The protocols converge across sports medicine clinics, recovery-focused training programs, and the peptide-research literature.
This is the foundational layer in a tactical, legal performance approach to coming back from injury. It runs alongside the work that always mattered: load progression, sleep, protein, the rehab basics. Used by many in the recovery / biohacking space who have already tried the conservative route and want the tactical breakdown rather than the marketing version.
BPC-157 is not a painkiller. Pain reduction shows up week one. Structural repair runs on its own clock. That gap is where re-injury lives. The peptide accelerates the curve. It does not skip it.
Dose for injury recovery
Research protocols and user reports converge on 250 to 500 mcg per day subcutaneous, often split AM and PM because BPC-157 runs short (~4 hour half-life subcutaneous). Localised injection near the injury site is common where the anatomy is accessible and safe. Standard ramp is 250 mcg/day for the first week, then 500 mcg/day for the remainder. Oral routes exist (BPC-157 has documented oral bioavailability) but most tactical recovery protocols default to subcutaneous for predictable plasma levels.
Cycle length
4–6 weeks on, 2 weeks off is the default. For acute injuries inside the active inflammatory window, continuous use across 4–8 weeks then reassess is common. Continuous use beyond 12 weeks has weak supporting literature. Cycling is the conservative move.
Stack pairings
Commonly stacked with TB-500.
Expected timeline
Week 1–2: pain on movement starts to drop. Recovery between training sessions feels noticeably faster. Week 3–4: inflammation visibly down, range of motion better. Structural remodeling is underway but not yet measurable from the outside. Week 6–8: meaningful plateau on most soft tissue injuries. This is the reassessment point. Chronic or severe injuries usually need a second cycle after a 2-week washout.
Common mistakes
- Stopping at the first sign of pain relief. Pain leaves before structure heals. You are not done until week six minimum.
- Stacking with daily NSAIDs. The inflammation-resolution signaling BPC-157 relies on gets blunted by chronic anti-inflammatory load.
- Hammering the same injection site for weeks. Rotate. Local irritation and lipoatrophy show up if you do not.
- Going straight to 500 mcg without titrating from 250. A one-week ramp gives you a clean read on individual sensitivity.
- Cheap reconstitution. Degraded peptide is the most common reason a protocol underperforms. The vial is not where you save money.